
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical gel containing loratadine, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing loratadine are listed in tablet, solution and capsule forms. It is also a component of FDA-approved kits.
Gel bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Loratadine is a non-sedating second-generation antihistamine for allergies that compounding pharmacies can prepare as oral liquids, capsules and other oral forms.
Loratadine is a second-generation antihistamine. It blocks histamine H1 receptors in the body, which reduces sneezing, runny nose, itching and watery eyes, and it crosses into the brain only minimally, so it usually does not cause drowsiness. It is FDA-approved for allergic rhinitis (hay fever) and urticaria (hives) and is sold over the counter, for example as Claritin tablets (Bayer), labeled for temporary relief of hay fever and other upper respiratory allergy symptoms. It also comes as orally disintegrating tablets, chewable tablets, capsules, a liquid, and in combination with pseudoephedrine (Claritin-D). A prescriber may order loratadine compounded in a strength or flavor not sold, or free of dyes, sugar, aspartame or other ingredients a patient cannot take. Compounded preparations are not FDA-approved and require a prescription.
Loratadine does not carry a boxed warning. Do not use it if you have ever had an allergic reaction to it or its ingredients, and stop and get medical help right away for rash, hives, trouble breathing or swallowing, or swelling of the face, lips, tongue or throat. Ask your prescriber before use if you have liver or kidney disease, because you may need a different dose. Taking more than directed may cause drowsiness. Children under 6 should use it only as a doctor directs. Some chewable tablets contain aspartame, which matters for people with phenylketonuria. If you are pregnant or breastfeeding, ask a health professional before use. LactMed notes milk levels are low and no infant effects are expected, but loratadine may reduce milk supply, especially when combined with pseudoephedrine. Talk to your prescriber or pharmacist about any side effect.
Loratadine is a piperidine H1 receptor antagonist that crosses the blood-brain barrier only minimally because of P-glycoprotein efflux. Per StatPearls, onset is usually within 1 to 3 hours with peak effect at 8 to 12 hours; plasma protein binding is 97% to 99% (desloratadine 73% to 76%). It is metabolized mainly by CYP3A4 and CYP2D6 to the active metabolite desloratadine, which is further metabolized by CYP2C8 after UGT2B10 glucuronidation. About 40% of a dose is recovered in urine and 42% in feces as conjugated metabolites, under 1% unchanged; half-life is about 8 hours for loratadine and about 28 hours for desloratadine. StatPearls recommends a longer dosing interval in renal or hepatic insufficiency. Labeled uses: allergic rhinitis and urticaria; Claritin OTC labeling covers hay fever and upper respiratory allergy symptoms. Dosing is per prescriber. Monitor for hypersensitivity and for excess sedation at higher exposure, and review CYP3A4 and CYP2D6 interacting drugs. Loratadine is not a controlled substance.
Wash your hands. Apply the amount on your label to clean, dry skin and spread it in a thin layer. For a metered pump, your label states the number of presses. For a dosing syringe, push the plunger to the mark. Let the gel dry before covering with clothing. Wash your hands afterward and keep the site from touching other people until it has dried. Do not apply to broken skin unless told to.
A gel can have a nonaqueous or a water-based base, and USP <795> sets its default beyond-use date by water content, not by the word gel. A nonaqueous gel usually carries a beyond-use date of up to 180 days at room temperature or refrigerated. A water-based gel carries up to 35 days with a preservative, or 14 days refrigerated without one. Your label states which applies. Keep the container closed, away from heat and open flame if it contains alcohol, out of reach of children, and discard after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)